Showing results (31-40 of 41) with videos related to

Sort By:
Pageof 5
ESMO Gastrointestinal Oncology|February 6, 2026
Comparative efficacy of PD-1 blockade in patients with dMMR/MSI-H metastatic colorectal or gastric cancer: a global retrospective studyG Mazzoli, F Nichetti, K Shitara, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|October 2, 2019
Impact of age and gender on the safety and efficacy of chemotherapy plus bevacizumab in metastatic colorectal cancer: a pooled analysis of TRIBE and TRIBE2 studiesF Marmorino, D Rossini, S Lonardi, et al.
ESMO Open|November 8, 2025
Second-line 5-FU plus nanoliposomal irinotecan versus FOLFOX/XELOX in metastatic pancreatic cancer after gemcitabine-nab-paclitaxel failure: a propensity score-matched analysisG Trovato, D Rossini, A Guidolin, et al.
ESMO Gastrointestinal Oncology|March 27, 2026
Effectiveness of FTD/TPI plus bevacizumab and impact of prior bevacizumab exposure in patients with mCRC: the Italian FLOWER studyG Trovato, M Carullo, A Nicastro, et al.
Pancreatology : Official Journal of the International Association of Pancreatology (IAP) ... [Et Al.]|October 10, 2024
Survival analysis of the metastatic cohort of Italian Association of Medical Oncology (AIOM) GARIBALDI surveyM Reni, E Giommoni, F Bergamo, et al.
British Journal of Cancer|April 10, 2014
Multivariate prognostic factors analysis for second-line chemotherapy in advanced biliary tract cancerL Fornaro, S Cereda, G Aprile, et al.
British Journal of Cancer|October 25, 2017
Dihydropyrimidine dehydrogenase pharmacogenetics for predicting fluoropyrimidine-related toxicity in the randomised, phase III adjuvant TOSCA trial in high-risk colon cancer patientsA Ruzzo, F Graziano, Fabio Galli, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|October 20, 2025
Re-treatment with panitumumab followed by regorafenib versus the reverse sequence in chemorefractory metastatic colorectal cancer patients with RAS and BRAF wild-type circulating tumor DNA: the PARERE study by GONOP Ciracì, M M Germani, F Pietrantonio, et al.
ESMO Open|June 20, 2025
Impact of age and sex on the efficacy and safety of ramucirumab plus paclitaxel as switch maintenance versus continuation of first-line oxaliplatin-based chemotherapy: a subgroup analysis of the ARMANI phase III trialR Fazio, G Randon, F Bergamo, et al.
ESMO Gastrointestinal Oncology|February 6, 2026
ItaLynch: an ongoing Italian study to evaluate the feasibility of mainstreaming the diagnosis of Lynch syndrome in colorectal cancer patientsA Puccini, F Grillo, M Fassan, et al.
Pageof 5